Komori
Governance4528ONO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Corporate Governance Report 2026/09/30

Reported on the activities of the Board of Directors and Board of Corporate Auditors in fiscal 2025, as well as the performance metrics and results used to evaluate executive compensation. The Board of Directors consists of 6 members, including 3 outside directors, and the Board of Corporate Auditors consists of 4 members, including 2 outside corporate auditors.

Worth reading
38Recurring
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit & Supervisory Board
Number of directors6 (including 3 outside directors)
Policy on cross-shareholdings

The Board of Directors conducts individual reviews of cross-shareholdings. The policy for reducing holdings, the number of holdings and their value are Not disclosed

Policy regarding shares of other companies held to maintain business relationships and for other purposes.

Changes this time

Reports on the activities of the Board of Directors and Board of Corporate Auditors in fiscal 2025, as well as the performance metrics and results used to evaluate executive compensation. The items explicitly identified as changes from the previous report are Not disclosed

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit & Supervisory Board
Number of directors6 (including 3 outside directors)
Policy on cross-shareholdingsThe Board of Directors conducts individual reviews of cross-shareholdings. The policy for reducing holdings, the number of holdings and their value are Not disclosed
Changes this timeReports on the activities of the Board of Directors and Board of Corporate Auditors in fiscal 2025, as well as the performance metrics and results used to evaluate executive compensation. The items explicitly identified as changes from the previous report are Not disclosed
Items this document does not state (4)
Number of independent officersCommitteeTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To disclose the activities of the Board of Directors and Board of Corporate Auditors, the transparency of executive compensation, and the degree of achievement of performance targets.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2026/09/30 | ONO PHARMACEUTICAL CO.,LTD. (4528) timely disclosure | Komori